Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467058 | 1.00 | LMNA (0.40) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL17154815 | 1.00 | LMNA (0.40) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL31201731 | 1.00 | LMNA (0.40) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL17154813 | 1.00 | LMNA (0.40) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL179333 | 0.81 | LMNA (0.50) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL2236698 | 0.80 | ADRA2A (0.38) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL21762128 | 0.79 | LMNA (0.41) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL4193375 | 0.78 | P2RX7 (0.46) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL4356472 | 0.77 | LMNA (0.40) | LMNAKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL2760656 | 0.77 | ADRB2 (0.43) | LMNAKMT2AMEN1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731963-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-22 | — | — | US | disclosed |
| US-11731963-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-22 | — | — | US | disclosed |
| US-11731963-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-22 | — | — | US | disclosed |
| CN-110198945-B | Process for preparing thiazolidinedione compounds and salts thereof | 米尼奥尔克斯治疗有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20220204496-A1 | PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]-METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2022-06-30 | — | — | US | disclosed |
| US-20220204496-A1 | PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]-METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2022-06-30 | — | — | US | disclosed |
| EP-3559010-B1 | PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF | MINORYX THERAPEUTICS S L (ES) | 2022-06-08 | — | — | EP | disclosed |
| EP-3559010-B1 | PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF | MINORYX THERAPEUTICS S L (ES) | 2022-06-08 | — | — | EP | disclosed |
| US-11124505-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof | MINORYX THERAPEUTICS S.L. (ES) | 2021-09-21 | — | — | US | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-0579733-B1 | THIAZOLIDINEDIONE DERIVATIVES, PRODUCTION AND USE THEREOF | UPJOHN CO (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5441971-A | Antidiabetic agents | THE UPJOHN COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0579733-A1 | THIAZOLIDINEDIONE DERIVATIVES, PRODUCTION AND USE THEREOF | PHARMACIA & UPJOHN COMPANY (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992018501-A1 | THIAZOLIDINEDIONE DERIVATIVES, PRODUCTION AND USE THEREOF | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204496-A1 | PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]-METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF | CYP3A5, CYP3A4, UGT1A4 | LMNA 3341/4885KMT2A 2288/4885MEN1 2124/4885 |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | LMNA 822/4885KMT2A 854/4885MEN1 763/4885 |
| US-11124505-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof | CYP3A5, UGT1A4, CYP4B1 | LMNA 3349/4885KMT2A 2066/4885MEN1 2431/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | LMNA 4065/4885KMT2A 2995/4885MEN1 4658/4885 |
| US-11731963-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof | CYP3A5, CYP3A4, UGT1A4 | LMNA 3341/4885KMT2A 2288/4885MEN1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.